CAR-T as a mirror of the future: are systems ready for complex interventions?

CAR-T therapy clearly demonstrates that the era of "complex medical interventions" is already here: the outcome depends not only on the molecule but also on a multitude of factors—patient routing, service coordination, workforce competencies, infrastructure, funding, and regulation.

A Canadian review uses CAR-T as a test to assess the health system's readiness for new complex technologies and identifies lessons relevant to all countries.

Why it's a "mirror of the future"

CAR-T was the first technology to require a restructuring of the entire healthcare system. Today, its use is expanding—from niche indications to earlier lines of therapy and new nosologies. The horizon now includes not only oncohematology but also solid tumors and autoimmune diseases.

This isn't just adding another drug to the formulary—it's a requirement to restructure care delivery models. Where the system fails to keep up, access delays occur, inequality grows, and years of life are lost. The review estimates that just a six-month delay in introducing new indications for certain groups (for example, DLBCL and refractory myeloma) can cost hundreds of years of life per population. This equates to approximately 1.3 years of life lost for every day of delay.

Main Challenges

According to the review "Canadian healthcare systems preparedness for the future of complex interventions: Lessons from T-cell redirecting therapies" (2025), the system faces barriers:

• Strict regulation hindering the development of academic CAR-T and local manufacturing;

• Lack of long-term capacity and workforce planning;

• Limited models of care due to linkage to transplant programs;

• Funding that does not reflect real system costs;

• Uncertainty in the clinical and economic evaluation of technologies.

Proposed Solutions

• Specialized regulatory pathways for academic CAR-T (the "hospital exception") —> development of local programs and cost reduction;

• Mechanisms for "horizon scanning" and long-term planning of personnel and infrastructure;

• Cell and gene therapy programs as sustainable platforms not tied to transplantology;

• New models of care (hub-and-spoke model): hubs (large centers) for high-tech procedures, spokes (regional branches) for monitoring and collaborative patient management with telemedicine;

• Revision of financing approaches: flexible instruments (risk-sharing agreements, outcome-based contracts);

• Development of clinical and economic evaluation practices and systematic collection of RWD.

The Main Lesson

CAR-T is not an exception, but a harbinger of a whole class of complex technologies. Their implementation requires healthcare to be prepared for institutional changes:

• creating new models of care,

• developing financing mechanisms,

• implementing transparent value assessment.

Where organizational mechanisms and programs are created, innovation begins to take hold. Where they don't exist, even the most breakthrough technologies risk remaining inaccessible.

Full text of the review: Lessons from T-cell re-directing therapies. Canadian healthcare systems preparedness for the future of complex interventions (https://drive.google.com/file/d/1g_zAb2DtfNxhiJf9XmNiswFlHAGynVbJ/view?usp=sharing)